On the basis of predicted amino acid sequence characteristics, herpes simplex virus type 1 gene UL10 is thought likely to encode a membrane protein with eight potential transmembrane regions. Previously, a protein with an apparent M r 47 000 on SDS-PAGE was identified as a product of this gene. Here we have further characterized this protein, and show that it is modified by N-linked glycosylation, associates with membranes from infected cells, and is a component of the virus particle. It is not essential for virus growth in tissue culture. To investigate its role in vivo a deletion mutant lacking the majority of the UL10 open reading frame was constructed (ULlO-del). The in vitro growth properties of this virus were consistent with previous studies; it grew to give slightly lower yields than wild-type and revertant viruses, and had no apparent temperaturesensitive or host range phenotype. In vivo, in a mouse model, ULlO-del was capable of establishing a latent infection, although it was impaired for growth at the periphery, and for spread to and/or growth within the nervous system relative to wild-type or revertant viruses. 0001-14690001- © 1993 
Introduction
Membrane proteins of enveloped viruses have a number of important functions. They are involved in virus entry into and egress from cells, may mediate transport across virion or infected cell membranes and are often key participants in virus interactions with the host immune system. Herpes simplex virus type 1 (HSV-1) encodes a large number of membrane proteins. Of the 73 distinct gene products so far predicted to be encoded by the HSV-1 genome, 20 contain a possible signal sequence and/or one or more potential transmembrane domains (McGeoch et al., 1985 (McGeoch et al., , 1988 Barker & Roizman, 1992) . To date, 10 HSV-l glycoproteins have been identified, and some of these have been extensively studied (for reviews see Spear, 1985 Spear, , 1993 Marsden, 1987) . However, little is known about the other potential membrane proteins.
The products of four virus genes (UL10, UL20, UL43 and UL53) are predicted to be membrane-inserted proteins with several transmembrane segments (McGeoch et al., 1988) . Both the UL20 and UL53 gene products contain four potential transmembrane regions, and the UL53 product also contains a signal sequence ~" Present address: Department of Pharmaceutical Science, Royal College, University of Strathclyde, 204 George Street, Glasgow G1 1XW, U.K. which is probably cleaved (Ramaswamy & Holland, 1992) . UL53 encodes a glycosylated polypeptide, gK, thought to be essential for virus replication (Hutchinson et al., 1992; Ramaswamy & Holland, 1992) . A single amino acid substitution within gK results in extensive cell-to-cell fusion (Debroy et al., 1985; Pogue-Geile & Spear, 1987) , suggesting a role in virus penetration, an event involving fusion between the virus and cell membranes. UL20 encodes a membrane-associated protein essential for virus growth in some, but not all, cell types, where it is required for the intracellular transport of the newly enveloped virus particles .
In contrast, no role has been described for the UL10 or UL43 gene products. Neither of these genes is essential for virus growth in tissue culture, although inactivation of UL10 does impair growth of the virus MacLean et al., 1991) . We were interested in investigating further the role of UL10. UL10 encodes a polypeptide which is predicted to contain eight potential transmembrane segments, including a signal sequence if the second in-frame initiation codon is used, and two potential sites for N-linked glycosylation. A protein synthesized predominantly late in infection, with an apparent Mr47000 following SDS-PAGE, has been identified as a product of this gene (MacLean et al., 1991) . The existence of corresponding open reading frames (ORFs) in other herpesvirus genomes, including varicella-zoster virus (VZV), Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), equine herpesvirus type 1 (EHV-1) and herpesvirus saimiri (HVS) (Albrecht et al., 1992; Baer et al., 1984; Davison & Scott, 1986; Lehner et al., 1989; Telford et al., 1992) , suggests an important role for UL10 in the natural life cycle of the virus. In this communication, we have further characterized the UL10 polypeptide and investigated the effect of deleting the majority of the UL10 ORF on virus growth in vivo.
Methods
Cells. BHK-21 clone 13 (C13) cells (Macpherson & Stoker, 1962) were grown in Eagle's MEM supplemented with 10% newborn calf serum.
Virus. HSV-1 strain 17syn + (Brown et al., 1973) was the wild-type virus strain used in this study. ULIO-lacZ contains the Escherichia coil lacZ gene, under the control of the simian virus 40 early promoter, within the UL10 ORF (MacLean et al., 1991) . The thymidine kinasenegative virus X4 has been described previously (MacLean & Brown, 1987) .
Plasmids. Plasmid construction and propagation were carried out by standard procedures (Maniatis et al., 1982) . In the following descriptions HSV-1 DNA sequences are numbered according to McGeoch et al. (1988) . Plasmid pC73.1 contains a 3.5 kb BamH~BglII fragment (residues 21655 to 25153), encompassing the UL10 ORF (residues 23 206 to 24 627, including the termination codon), within the BamHI site of pUC19. PpuMI-digested pC73.1 was blunt-ended with the Klenow fragment of DNA polymerase, digested with Bali and religated, resulting in a plasmid lacking the HSV DNA sequences from residues 23 606 to 24 594 inclusive (pC122). To introduce a novel XbaI site within the intragenic region between genes UL10 and UL11, a SalI subfragment from pC73.1, containing HSV-1 sequences from residues 22872 to 25153, was cloned into the Sall site of pGem-1, generating plasmid pB3.1. MluI-digested pB3.1 was blunt-ended with the Klenow fragment and religated in the presence of an 8 bp XbaI linker. This effectively introduced a 12 bp insertion after HSV-1 residue 24771 (plasmid pC343).
Antiserum. The anti-UL10 serum was raised against the carboxyterminal region of UL10 (amino acids 458 to 467; MacLean et al., 1991) .
Construction of deletion and revertant viruses.
Transfections were carried out according to the procedure of Graham & van der Eb (1973) , as modified by Stow & Wilkie (1976) . C13 cells were cotransfected with 1 to 2 ~g of virus DNA and various amounts of linearized plasmid DNA, and the progeny virus were harvested and titrated as previously described (MacLean et al., 1991) . Cells were infected with approximately 20 p.f.u./50 mm Petri dish, and overlaid with methylcellulose containing 1 mM-X-gal if required. Virus from individual plaques was isolated and subjected to several further rounds of plaque purification. The genome structure of the individual isolates was determined by restriction enzyme analysis (MacLean et al., 1991) before virus stocks were grown.
Intracranial virulence. Three week old female BALB/c mice (B & K Universals) were inoculated intracerebrally with 10-fold serial dilutions of virus in PBS containing 5 % newborn calf serum. The mice were anaesthetized with halothane, and 25 pl of the appropriate virus dilution was used to inoculate the central region of the left cerebral hemisphere. Dilutions used were then titrated to confirm the input viral dose. Mice were observed daily for 10 days after inoculation and the LD~0 was calculated. Brains were removed from dead animals, homogenized and sonicated, and virus was then grown by plating approximately 10% of the resultant suspension onto a C13 cell mouolayer in a Linbro well. The resultant virus stocks were analysed by restriction enzyme digestion.
Latency studies. Five week old female BALB/c mice were inoculated in the right rear footpad with 25 lal of 10-fold serial dilutions of virus (four mice per virus dose) and the virus inoculum was confirmed by titration. Six to 8 weeks post-infection (p.i.) the mice were killed, and nine dorsal root ganglia (DRG; the two lowest thoracic, six lumbar and the upper sacral) were removed from the right-hand side of the spinal cord and placed separately in culture medium within microtitre wells. Ganglia were screened for release of infectious virus for 3 weeks, by transferring the culture medium every 2 to 3 days onto a C13 cell monolayer, and scoring for plaque formation or c.p.e.
Virus growth in vivo. Four week old female BALB/c mice were inoculated in the right rear footpad, as above. Animals were killed at various times p.i., and the right rear footpads, nine ipsilateral DRG (as above) and brainstem were removed and stored at -70 °C. To determine the virus titres present, the tissues were homogenized in Eagle's M EM containing 10 % newborn calf serum (final volume 1 ml), and the resultant suspension was titrated on C13 cells. Statistical analysis of the results was carried out using Student's t-test.
Preparation of infected cell extracts. Confluent cell monolayers in 50 mm Petri dishes were infected at a multiplicity of 20 in Eagle's MEM containing 5 % newborn calf serum. The virus was adsorbed for 1 h at 37 °C and the infected cells then washed twice with, and subsequently maintained in, Eagle's MEM containing one-fifth the normal concentration of methionine and 2 % newborn calf serum.
[35S]Methionine (Amersham; specific activity > 1000 Ci/mmol) was added directly to the cells at a final concentration of 50 laCi/ml at 3 h p.i. Infected cell polypeptides were harvested 24 h p.i. by washing the cells twice with PBS and then adding 0'5 ml extraction buffer containing 100 mM-Tris-HC1 pH 8.0, 10% glycerol, 0.5% NP40, 0.5% sodium deoxycholate and 0.2 mN-PMSF. Cell debris was removed by centrifugation at 11000 g for 10 rain in a Beckman microfuge and the supernatant was stored at -70 °C until use.
For glycosylation studies, infected cells were labelled either with [aH]mannose (Amersham; specific activity 30 to 60Ci/mmol) at 100 laCi/ml in PBS from 6 to 14 h p.i., or with [14C]glucosamine (Amersham; specific activity 50 to 60 mCi/mmol) at 10 to 20 gCi/ml in Eagle's MEM containing 2 % newborn calf serum, from 3 to 20 h p.i., and harvested as described above. To inhibit glycosylation events, cells were infected and maintained continually in either 2 gg/ml tunicamycin (which inhibits N-linked glycosylation), 10 gM-monensin (which inhibits Golgi apparatus function, i.e. both O-linked glycosylation and the processing of the N-linked moieties), or both.
Subcellularfractionation. Subcellular fractionation was based on the method described by Bryant &Ratner (1990) , with minor modifications. Cell monolayers, rinsed twice with PBS and once with distilled water, were scraped into homogenization buffer (20 mM-Tris-HC1 pH 8.0, 10 mM-MgC12, 0.5 m~-EDTA, 7 mM-2-mercaptoethanol) and swollen on ice for 20 min. After disruption of the cells by Dounce homogenization (50 strokes), intact cells and nuclei were removed by centrifugation at 2000 r.p.m, for 3 min at 4 °C in a Fisons Coolspin centrifuge, and the supernatant was then adjusted to 150 mM-NaC1 and centrifuged in a Sorvall Ti50 rotor at 45000 r.p.m, for 30 min at 4 °C. The supernatant (cytosol) was removed, and the pellet (total membranes) was then resuspended in homogenization buffer containing 1 M-NaCI and this was then centrifuged as before, to elute those proteins which bind to membranes at only low ionic strength. The final IP: 54.70.40.11
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Purification of virus particles. The procedure was essentially that described by Szil~igyi & Cunningham (1991) , with minor modifications. Cell monolayers in 80 oz roller bottles were infected at a multiplicity of 0.001, incubated at 31 °C until c.p.e, was evident, and then labelled with [3aS]methionine as described above. Once c.p.e, was complete, the culture supernatants were centrifuged in a Fisons Coolspin centrifuge (2000 r.p.m, for 30 min at 4 °C) to remove cell debris. Virions were centrifuged in a Sorvall GSA rotor (12000 r.p.m, for 2 h at 4 °C), resuspended gently in a small volume of Eagle's MEM without phenol red and layered on a 35 ml continuous 5 to 15 % Ficoll gradient which was centrifuged in a Sorvall AH629 rotor at 12000 r.p.m, for 2 h at 4 °C. Both the lower virion band and the upper, more diffuse band containing the light particles (nucleocapsid-free, tegument-envelope structures) were collected by side puncture, diluted and centrifuged in a Sorvall AH629 rotor at 21000 r.p.m, for 16 h at 4 °C. Purified virions and light particles were solubilized in extraction buffer prior to immunoprecipitation.
Immunoprecipitation. lmmunoprecipitation reactions were carried out as described previously (MacLean et al., 1991) , and the samples were analysed on 5 to 12.5 % SDS-polyacrylamide gels, cross-linked with bisacrylamide (Marsden et al., 1978) , or on 10% SDSpolyacrylamide gels cross-linked with diallyltartardiamide (DATD; Szil~igyi & Cunningham, 1991) .
Fluorography. SDS~polyacrylamide gels were treated with EnaHance (New England Nuclear), dried and exposed to Kodak X-Omat XS-1 film at -70 °C.
Results
The ULIO protein associates with membranes from infected cells UL10 is predicted to encode a membrane protein (McGeoch et al., 1986) . To determine whether the UL10 polypeptide is membrane-associated, cytosol and membrane fractions were isolated from infected ce!ls labelled with [~SS]methionine, and immunoprecipitated with the anti-UL10 serum (see Methods). From Fig. 1 it can be seen that the UL10 encoded polypeptide associated with the membrane fraction, and that this interaction was stable in the presence of 1 M-NaC1. At this concentration NaC1 elutes proteins that associate only weakly with membranes, but does not affect the more strongly associated or integral membrane proteins. In most experiments, the anti-UL10 serum specifically precipitated only a 47K polypeptide from infected cell extracts. Two additional higher M r bands were precipitated from membrane fractions (these can also be seen in the experiment in Fig. 2 a) . Since the pattern of these bands was reminiscent of gD, immunoprecipitations were also carried out using an anti-gD monoclonal antibody; these bands did not comigrate with gD ( Fig. 1) . It is likely that these represent alternative processed forms of the UL10 encoded polypeptide, not normally apparent in precipitations from total cell extracts due to comigrating bands in this area of the gel. Increasing the amount of competing peptide did not prevent precipitation of these comigrating bands (results not shown).
The ULIO protein is modified by N-linked glycosylation
The UL10 encoded polypeptide contains two potential N-linked glycosylation sites. To determine whether this protein is glycosylated, extracts from cells infected in the presence of [3SS]methionine, [aH]mannose or [HC]glucosamine were immunoprecipitated with anti-UL10 serum (Fig. 2a ). The UL10 polypeptide was labelled weakly by both mannose and glucosamine, suggesting that it is glycosylated, at least to a minor extent. To determine whether the UL10 protein is modified by N-linked or Olinked glycosylation, cells were infected in the presence of tunicamycin, monensin or both, and labelled with [3~S]methionine. Cell extracts were then immunoprecipirated with anti-UL10 serum. The apparent M r of the UL10 polypeptide was reduced by about 3K following treatment with tunicamycin, but was not appreciably affected by monensin ( Fig. 2b; for clarity a thymidine kinase-negative virus was used in this experiment, as the UL10 protein migrates between the thymidine kinase and actin bands following tunicamycin treatment). Analysis on DATD cross-linked gels showed the mobility shift more clearly (Fig. 2 c) .
The ULIO protein is a virion component
The HCMV counterpart of UL10 protein is a virion component (Lehner et al., 1989) , and it seemed reasonable to expect that the HSV-1 UL10 protein would also be present in purified virus particles. Cells were infected with HSV-1 strain 17syn + in the presence of [~SS]methionine, and both virions and light particles (virus-like structures which lack a nucleocapsid, but contain the tegument and envelope components) were purified on Ficoll gradients, solubilized and then immunoprecipitated with anti-UL10 serum. The UL10 protein was detected in both virions and light particles, but only on long exposures of the gels (results not shown). In an attempt to improve detection, similar experiments were carried out with HSV-1 strain F, which grows to higher titres than strain 17syn +. The UL10 polypeptide could be precipitated from both the strain F virions and light particles (Fig. 3) .
Construction of ULIO deletion and revertant viruses
We previously constructed a ULlO-lacZ insertion mutant; this virus could potentially encode a truncated UL10 protein containing all the transmembrane regions of the intact product (MacLean et al., 1991) . Therefore, to investigate the role of UL l0 in vivo, we first deleted the majority of the UL10 ORF. Plasmid pC122 contains HSV DNA sequences encompassing UL10, but lacking 989 bp from within the UL10 ORF (see Methods, and Fig. 4 ). This construct potentially encodes a polypeptide possessing the N-terminal 133 amino acids of the full-length (473 amino acid) UL10 product, containing only the first two transmembrane domains, and a novel 92 amino acid C terminus. This mutation was recombined into the virus genome by cotransfecting C13 cells with ULIO-laeZ virus DNA and plasmid pC122 (see Methods). Recombinant viruses were detected by their clear plaque morphology in the presence of X-gal. Purified virus was analysed by restriction enzyme digestion of 32p-labelled viral DNA (results not shown), and one isolate, designated ULIOdel, was chosen for further study.
To ensure that any observed growth alterations resulted from the introduced mutation, revertant viruses were generated. C 13 cells were cotransfected with ULIOdel virus DNA and either a plasmid containing the wildtype UL10 ORF (pC73.1), or a plasmid with a 12 bp insertion within the intragenic region between UL10 and U L l l , introducing an XbaI site (pC343). The latter plasmid was included as a control, to ensure that any wild-type isolates arose through recombination, and not through wild-type contamination. Recombinant viruses were readily detected by virtue of their larger plaque morphology, and their genome structures were analysed by restriction enzyme digestion. None of 22 large plaque isolates from control transfections lacking plasmid DNA had a wild-type genotype, while 11 / 11 wild-type isolates from the transfections with pC343 contained the novel XbaI site (results not shown). We were therefore confident that all the wild-type isolates represented true revertant virus. Two 'wild-type' and two 'XbaI +' revertants were purified, and working stocks grown. These viruses grew indistinguishably following infection at low multiplicity (Fig. 5), and one' wild-type' revertant  (rev-2) was chosen as the prototype ULlO-rev virus for subsequent studies. In vitro growth properties of UL10-del ULlO-del, like ULlO-lacZ, consistently showed a smaller plaque morphology than the wild-type or revertant viruses. A pattern of growth similar to that of the wildtype viruses was seen following infection of C13 cells at low multiplicity, but ULlO-del reached yields 10-to 20fold lower than the controls (Fig. 5 ), and about twofold lower than its parent virus, ULlO-lacZ (not shown). Following infection at high multiplicity, ULlO-del reached a final yield one-to sevenfold lower than that of the revertant virus in a variety of cell types tested (C13, MDCK, MA104, Vero, CV-1, BSC-1, HeLa and Flow 2002) , and about 18-fold lower in FG cells. ULlO-del was no more impaired for growth in resting C13 cells (three-to sevenfold reduced yields), nor was the plaquing efficiency of ULlO-det notably different at 31 °C, 37 °C or 39.5 °C (not shown).
In vivo growth properties of UL10-del
The ability of the UL10 deletion mutant to replicate in vivo at the periphery and to spread to and replicate within the nervous system was compared with that of the wild-type and revertant viruses. Mice were inoculated in the footpad as described (Methods) and virus titres in the footpad, DRG and brainstem measured at various times p.i. Initial experiments were carried out using an input dose of 1 x l0 G p.f.u./mouse, the peripheral LDs0 of our wild-type stock (both ULlO-del and ULlO-rev had a peripheral LD~0 > 107 p.f.u.). Although both wild-type and ULlO-rev viruses could be detected in the DRG and brainstem, ULlO-del was detectable only at the periphery, and at a significantly lower level than ULlO-rev (P < 0.02). Even at the highest possible input dose (5-4 x 107 p.f.u.), ULlO-del was only barely detectable in the DRG, and did not reach detectable levels in the brainstem (Fig. 6) . At this dose, the amount of ULlO-del virus present at the periphery was similar to that found when using 50-fold less ULlO-rev. These results suggest that ULlO-del is impaired in its ability to grow at the periphery, and to spread to and/or grow within the nervous system, in the mouse footpad model.
To determine whether ULlO-det could establish and reactivate from a latent infection, mice were inoculated in the right rear footpad with 10-fold serial dilutions of virus (four mice per group), and nine ipsilateral ganglia per mouse were explanted 6 to 8 weeks p.i. The ganglia were screened individually for release of infectious virus over a 3 week period. Results are shown in Table 1 . At each dose tested, similar numbers of mice infected with ULlO-del and ULlO-rev developed a detectable latent infection. Thus, ULlO-de! is capable of establishing and reactivating from a latent infection. However, ULlO-del was slower to reactivate following explantation, generally taking 2 to 4 days longer than ULlO-rev to score positive (not shown), and did not appear to spread as efficiently through the nervous system as the wild-type or revertant viruses; only one or two ganglia per mouse scored positive, even with the highest input dose (Table 1) .
The impaired spread of virus through the nervous system could be due to the lower titres of virus reaching the ganglia, or to an inability of the virus to grow in nervous tissue. To determine whether ULlO-del could replicate within the nervous system, the neurovirulence of the UL10 deletion mutant was compared to wild-type and revertant viruses. Mice were inoculated intracerebrally with 10-fold serial dilutions of virus, and deaths from encephalitis by 10 days p.i. scored (Table 2) . ULlO-del appeared to be slightly less pathogenic than its revertant virus, with a LDs 0 of 3"5 x 103 compared to 1 x 102p.f.u./mouse. Restriction enzyme analysis of virus recovered from the brains of dead animals confirmed that these deaths were caused by ULIO-del, and were not the result of wild-type contamination.
Limitations of the in vivo model
Although ULlO-det appeared to be impaired for growth in vivo compared to ULlO-rev, it was nevertheless capable of replication both at the periphery and within the 
ULlO-rev
ULlO-del 10 7 -1,1,1,2" 10 6 6,8t 4,8,4,7 0,1,2,1 10 5 1,3,1,1 1,1,0,0 1,1,0,1 10 4 1,1,0,1 0,0,0,1 0,0,0,1 * Number of ganglia/mouse yielding infectious virus. ~ Two mice from this group died following the acute infection. ULlO-del at high input dose (but still less than the LDs0 ) caused severe leg swelling and lesions in almost all animals. Thus, the dose of ULlO-del required for efficient spread to the nervous system could not be established. Furthermore, ULlO-rev appeared to be impaired in its ability to spread to and/or replicate within the nervous system, compared to the wild-type virus. Infection with 1 x 106p.f.u. wild-type 17syn + produced significantly higher peak titres in the DRG (P < 0-05) and brainstem (P < 0.02) than infection with 1.7 x 10 s p.f.u. ULlO-rev, although ULlO-rev reached significantly higher titres in the footpad (P < 0'01) (compare results above with Fig. 6 ). Whether this impairment is due to a secondary mutation which arose during the generation of ULlO-del or ULlO-rev, or whether it simply reflects individual plaque variation pre-existing within the wild-type stock used to generate ULlO-del, is unclear. Interestingly, 10 individual plaque isolates of wild-type 17syn + were found to vary in intracranial LDs0, from < 10 to 100 p.f.u. (L. Robertson, unpublished). The intracranial LD.5 o of ULlO-rev is within this range (100 p.f.u.), but at the less virulent extreme. Analysis of individual plaque variation in peripheral LD~0 has not been carried out.
Discussion
HSV-1 gene UL10 is predicted to encode a very hydrophobic protein with eight potential transmembrane segments (McGeoch et al., 1986) . Two potential Nlinked glycosylation sites are present within the predicted amino acid sequence of the UL10 protein, and one of these is conserved in all other known corresponding herpesvirus ORFs (VZV gene 50, Davison & Scott, 1986; EHV-1 gene 52, Telford et al., 1992; EBV gene BBRF3, Baer et al., 1984; HCMV gene UL100, Lehner et al., 1989; Chee et al., 1990; HSV gene 39, Albrecht et al., 1992) . These features would suggest that the UL10 product is a glycosylated membrane protein. The results presented here support this prediction. In cell fractionation experiments, the UL10 polypeptide was found to be associated with infected cell membranes, it also was labelled weakly by both [3H]mannose and [14C]glucosamine and had a higher electrophoretic mobility when synthesized in the presence of tunicamycin, an inhibitor of N-linked glycosylation. The poor incorporation of mannose and glucosamine, and the relatively small change in M r with tunicamycin treatment, would suggest that the 47K UL10 protein is not heavily glycosylated. The two additional higher M r species specifically precipitated from membrane fractions by the anti-UL10 serum probably represent alternatively processed forms of the UL10 protein, and would appear to be at least as abundant as the 47K species. We are currently trying to determine whether they represent more highly glycosylated forms of the UL10 product.
The UL10 product is dispensable for growth in tissue culture MacLean et al., 1991) . Although we had previously constructed a ULIO-lacZ insertion mutant, we could not exclude the possibility that this virus synthesized a partially functional UL10 protein (MacLean et al., 1991) . Therefore, to investigate the role of UL10 in vivo, we first deleted the majority of the UL10 ORF (since UL10 overlaps UL9, an essential gene, we could not simply delete the entire UL10 ORF). The deleted gene retains only the first two transmembrane segments, and is therefore unlikely to encode a functional UL10 product.
In agreement with the previous studies, ULlO-del is impaired for growth in tissue culture, and does not have an obvious temperature-sensitive or host range phenotype. In addition, it is no more impaired for growth in resting as compared to exponentially growing cells (results not shown). In vivo, ULlO-del is impaired for growth at the periphery, and for spread to and/or growth within the nervous system, in a mouse model: following footpad inoculation, ULlO-del grew less well at the periphery than control viruses did, and was barely detectable in the DRG. It was capable of establishing a latent infection and reactivating following explantation, but, unlike ULlO-rev, only those ganglia directly innervating the site of inoculation appeared to be involved; and the intracranial LDs0 of ULlO-del was approximately 35-fold higher than that of the revertant virus. The level of impairment in growth in vivo is difficult to quantify, but is compatible with the in vitro growth properties of this virus: i.e. there is no evidence that UL10 has a specific in vivo role not detectable in tissue culture assays.
In this communication we show that HSV-1 gene UL 10 encodes a glycosylated membrane protein required for optimal virus growth both in vitro and in vivo. Like its HCMV counterpart (Lehner et al., 1989) , the UL10 protein is a virion component, presumably located within the virus envelope. However, the precise function of the UL10 protein is still unclear. In contrast to the other multiply inserted membrane proteins encoded by HSV-1, the highest similarity between the UL10 protein and its counterparts in the other herpesviruses lies within the transmembrane regions (it should be noted that overall amino acid similarity is low). This would not be expected if the transmembrane regions simply serve a structural role, and may favour a role for this protein in transmembrane transport events. Elucidation of the structure of the UL10 protein within the membrane, and the development of functional assays, will be important to determine whether this is indeed the case.
